The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

PURPOSE: We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies. METHODS: In Study 1, subjects with normal hepatic function or mild, moderate,...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Horak, J, White, J, Harris, A, Verrill, M, Carmichael, J, Holt, A, Cantarini, M, Macpherson, M, Swaisland, A, Swaisland, H, Twelves, C
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2011

Gelijkaardige items

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
door: Dean, E, et al.
Gepubliceerd in: (2012)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
door: Marbury T, et al.
Gepubliceerd in: (2017-02-01)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
door: Hajer AlRasheed, et al.
Gepubliceerd in: (2022-11-01)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
door: Boss, D, et al.
Gepubliceerd in: (2010)

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
door: Kit Wun Kathy Cheung, et al.
Gepubliceerd in: (2024-04-01)

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients
door: Ran Ren, et al.
Gepubliceerd in: (2024-12-01)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
door: Borin MT, et al.
Gepubliceerd in: (2019-10-01)

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
door: Rajinder Bhardwaj, et al.
Gepubliceerd in: (2024-07-01)

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
door: Aliyah Almomen, et al.
Gepubliceerd in: (2020-09-01)

Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment
door: Christine C. Hsu, et al.
Gepubliceerd in: (2022-03-01)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
door: Kunz C, et al.
Gepubliceerd in: (2016-03-01)

Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis
door: Teppei Yamaguchi, et al.
Gepubliceerd in: (2015-02-01)

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
door: Mei-Chuan Tang, et al.
Gepubliceerd in: (2015-01-01)

Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment
door: Mirjam Kuipers, et al.
Gepubliceerd in: (2006-01-01)

Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
door: Wei Yin, et al.
Gepubliceerd in: (2024-08-01)

Gefitinib and EGFR gene copy number aberrations in esophageal cancer
door: Petty, RD, et al.
Gepubliceerd in: (2017)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
door: Yuta Nio, et al.
Gepubliceerd in: (2022-11-01)

Mucocutaneous side effects of gefitinib
door: Ruhaila Thekkath, et al.
Gepubliceerd in: (2021-01-01)

Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
door: Watson, J, et al.
Gepubliceerd in: (2019)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
door: Jun Li, et al.
Gepubliceerd in: (2020-02-01)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
door: Harada Masao, et al.
Gepubliceerd in: (2007-03-01)

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
door: Nicola Ferri, et al.
Gepubliceerd in: (2024-08-01)

Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver
door: Jovanović Marija, et al.
Gepubliceerd in: (2023-01-01)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
door: Hongbo Zhao, et al.
Gepubliceerd in: (2018-11-01)

Pharmacokinetics of bempedoic acid in patients with renal impairment
door: Benny M. Amore, et al.
Gepubliceerd in: (2022-03-01)

Acute hepatitis of non-specified etiology
door: Ye. V. Tsyganova, et al.
Gepubliceerd in: (2011-02-01)

Pyogenic Granuloma in a Patient on Gefitinib
door: António Fernandes Massa, et al.
Gepubliceerd in: (2016-06-01)

Predicting Tumor Responses to Gefitinib and Erlotinib.
Gepubliceerd in: (2005-01-01)

Triggering of Suicidal Erythrocyte Death by Gefitinib
door: Abdulla Al Mamun Bhuyan, et al.
Gepubliceerd in: (2017-03-01)

Urinary Neopterin in Patients Treated with Gefitinib
door: Kalabova Hana, et al.
Gepubliceerd in: (2007-02-01)

Busting the Breast Cancer with AstraZeneca’s Gefitinib
door: S. Chemmalar, et al.
Gepubliceerd in: (2023-01-01)

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
door: Anthoney D, et al.
Gepubliceerd in: (2012-11-01)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
door: Tatsuya Nagano, et al.
Gepubliceerd in: (2011-01-01)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
door: Shuang Zhao, et al.
Gepubliceerd in: (2021-11-01)

Evaluation of the efficiency of the hepatoprotector glucuronate in toxic hepatitis of various etiology
door: R. N. Akalaev, et al.
Gepubliceerd in: (2024-10-01)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
door: Lei Sun, et al.
Gepubliceerd in: (2021-09-01)

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment
door: Kelly E. Duncan, et al.
Gepubliceerd in: (2024-12-01)

Features of the course and outcomes of neonatal hepatitis of various etiologies
door: N. A. Efremova, et al.
Gepubliceerd in: (2014-09-01)

Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model
door: Flavia Storelli, et al.
Gepubliceerd in: (2024-01-01)

Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment
door: Fan Mou, et al.
Gepubliceerd in: (2024-12-01)